Seaport pharma firm launches world's most expensive medicine

• The Seaport's Orchard Therapeutics won approval for Lenmeldy Monday.

Around 40 children are born with the genetic disorder treated by Lenmeldy — metachromatic leukodystrophy — in the U.S. each year, according to CNN.

• Makers of the new drug claim it can slow or even stop the progression of MLD with a single dose.

The bottom line: Instead of charging patients over $4 million, the price is what insurers, including public payers like Medicaid, will have to pay for the treatment.